Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global ...

As of market close on Friday, Jan. 24, Moderna stock is up 21.6% this week. Here's why.

Based on its share price, down 75% in the last three years, it's easy to write off Moderna (NASDAQ: MRNA) as a biotech ...

"Diversity of supply and availability of vaccine formats such as pre-filled ... With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future ...

Our analyst team just revealed what they believe ... Moderna stock is up 21.6% this week. Here's why. Moderna works on mRNA vaccines, which use synthetic code to instruct the body to make specific ...

As Moderna (NASDAQ: MRNA) looks to shore up its business in the wake of its declining coronavirus vaccine sales, it's natural for investors to wonder about where the biotech will go in the near future ...